A new partner in NASCAR, Tandem Diabetes Care is dedicated to making the lives of people with diabetes better through relentless innovation and revolutionary customer experience.
Tandem Diabetes Care Reports Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
Tandem Diabetes Care notes all in-warranty t:slim X2 pump users in Canada will have the option to add Control-IQ technology to their existing pump beginning in March 2021 via remote software update.
Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.
Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
“Nearly 40,000 t:slim X2 users have updated their pump with our revolutionary Control-IQ technology,” said John Sheridan, president and CEO of Tandem Diabetes Care.
FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller Announced by Tandem Diabetes Care
The company reports this is the second system to receive iAGC designation by the FDA, following the Company’s clearance of the t:slim X2™ insulin pump with Control-IQ™ technology in December 2019.
Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results
9/25/18: “The sales momentum we are experiencing both domestically and internationally reinforces that we are successfully addressing the needs of people with diabetes worldwide,” said Kim Blickenstaff, President and Chief Executive Officer. “We are increasing our sales guidance as a reflection of this and the tremendous feedback we’ve been receiving on the t:slim X2 Insulin Pump.”
8/17/18: “This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care.
8/8/18: “The results seen in the PROLOG study demonstrate that an automated insulin delivery system can have a significant impact on glycemic control without being overly complicated or burdensome for the patient,” said Dr. Greg Forlenza, principal investigator for the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine.
12Page 1 of 2